Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Teligent Pharma, Inc.
WARNING LETTER
•Teligent Pharma, Inc.•May 20, 2019

Teligent Pharma, Inc. – FDA Warning Letter, May 20, 2019

Record Details

The FDA inspected Teligent Pharma, Inc. in Buena, NJ, from April 22 to May 20, 2019, identifying significant CGMP violations, rendering their drug products adulterated. The firm also failed to submit required NDA Field Alert Reports (FARs).

Key violations include: 1. **Inadequate Investigations (21 CFR 211.192):** The firm failed to thoroughly investigate OOS results in a timely manner, justify root causes, expand investigations, implement CAPAs, or evaluate CAPA effectiveness. Examples include clobetasol propionate lot 8922, which had OOS impurity results at release and two stability intervals but no market action, and flurandrenolide ointment lots 8071 and 8072 with failing related compounds results. 2. **Inadequate Stability Program (21 CFR 211.166(a)):** Stability samples were not tested within stipulated timeframes, leading to delayed OOS result investigations for products like Triamcinolone Acetonide Cream and LOPROX. 3. **Failure to Follow Complaint Procedures (21 CFR 211.198(a)):** Over half of 2018/2019 complaints remained open beyond 30 days, with some open over 150 days. The quality unit failed to adequately review complaints

Company
Teligent Pharma, Inc.
Inspection date
May 20, 2019
Product type
Drugs
Office
Division of Pharmaceutical Quality Operations I
Person
  • Diana Amador-Toro (District Director)
View Company Profile

ID · 825dc7ec-a2d0-4242-ae51-5ef8e5862271

Violation Codes10
21 CFR 21021 CFR 21121 CFR 314.81(b)(1)(ii)21 CFR 211.19221 CFR 211.166(a)21 CFR 211.198(a)21 CFR 211.100(a)21 U.S.C. 355(k)FD&C Act 501(a)(2)(B)FD&C Act 505(k)

Full citation text and observation details available on the Dashboard.

Other documents for Teligent Pharma, Inc.
  • 483 - 2021-08-31August 31, 2021
  • 483 - 2019-05-20May 20, 2019
  • EIR - 2017-10-19October 19, 2017
  • 483 - 2017-10-18October 18, 2017
  • EIR - 2016-01-22January 22, 2016

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Teligent Pharma, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.